Biomea Fusion Inc (BMEA) is a Healthcare · Biotechnology company listed on NASDAQ. Price $1.85 (+3.35%), Market cap $0.10B, 52-week low–high $0.96 ~ $2.90.
Biomea Fusion, Inc., a clinical-stage diabetes and obesity medicines company, focuses on the discovery and development of oral drugs to treat patients with diabetes and obesity. It's lead clinical program's drug candidates are COVALENT-111 and COVALENT-112, which has completed Phase II clinical trials of icovamenib for the treatment of Type 1 and Type 2 diabetes; COVALENT-211, which is in Phase II clinical trial of icovamenib for treating insulin-deficient type 2 diabetes; and COVALENT-212, which is in Phase II clinical trial of icovamenib for the treatment of type 2 diabetes. The company is also developing BMF-650, which is in Phase I glucagon-like peptide-131 clinical trial for the treatme
Financial statements, price targets, institutional (13F) holdings and related news for Biomea Fusion Inc are updated in real time on BlackAll Trade.
Biomea Fusion Inc trades at $1.85 (+3.35%). Real-time quotes and charts are available on BlackAll Trade.
Biomea Fusion Inc has a market cap of about $0.10B.
Biomea Fusion, Inc., a clinical-stage diabetes and obesity medicines company, focuses on the discovery and development of oral drugs to treat patients with diabetes and obesity. It's lead clinical pro